Publication Date
2-17-2022
Journal
Cancers
DOI
10.3390/cancers14041012
PMID
35205762
PMCID
PMC8870190
PubMedCentral® Posted Date
2-17-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
prostate cancer, cancer disparities, DNA damage, metabolism
Abstract
African Americans (AA) are two times more likely to be diagnosed with and succumb to prostate cancer (PCa) compared to European Americans (EA). There is mounting evidence that biological differences in these tumors contribute to disparities in patient outcomes. Our goal was to examine the differences in DNA damage in AA and EA prostate tissues. Tissue microarrays with matched tumor-benign adjacent pairs from 77 AA and EA PCa patients were analyzed for abasic sites, oxidative lesions, crosslinks, and uracil content using the Repair Assisted Damage Detection (RADD) assay. Our analysis revealed that AA PCa, overall, have more DNA damage than EA PCa. Increased uracil and pyrimidine lesions occurred in AA tumors, while EA tumors had more oxidative lesions. AA PCa have higher levels of UMP and folate cycle metabolites than their EA counterparts. AA PCa showed higher levels of UNG, the uracil-specific glycosylase, than EA, despite uracil lesions being retained within the genome. AA patients also had lower levels of the base excision repair protein XRCC1. These results indicate dysfunction in the base excision repair pathway in AA tumors. Further, these findings reveal how metabolic rewiring in AA PCa drives biological disparities and identifies a targetable axis for cancer therapeutics.
Included in
Biochemical Phenomena, Metabolism, and Nutrition Commons, Immunology of Infectious Disease Commons, Immunopathology Commons, Medical Immunology Commons, Oncology Commons, Pathology Commons